Differences in FMO2*1 allelic frequency between Hispanics of Puerto Rican and Mexican descent

Drug Metabolism and Disposition

Volumn 32, Issue 12, 2004, Pages 1337-1340

  Krueger, Sharon K ^a   Siddens, Lisbeth K ^a   Martin, Sarah R ^a   Yu, Zhen ^a   Pereira, Clifford B ^b   Cabacungan, Erwin T ^c   Hines, Ronald N ^c   Ardlie, Kristin G ^d   Raucy, Judy L ^e   Williams, David E ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d Genomics Collaborative Inc   (United States)

^e California Toxicol Res Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 IMIDAZOLIDINETHIONE; ANTU; DIMETHYLANILINE MONOOXYGENASE; DNA; DRUG METABOLIZING ENZYME; FLAVIN CONTAINING MONOOXYGENASE ISOFORM 2; GLUTATHIONE; PROTEIN FMO2Q472; PROTEIN FMO2X472; SULFENIC ACID DERIVATIVE; SULFOXIDE; UNCLASSIFIED DRUG; DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING); DRUG; ISOENZYME; OXYGENASE;

AFRICAN AMERICAN; ARTICLE; DRUG METABOLISM; ETHNIC DIFFERENCE; FMO2 1 GENE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENOTYPE; HISPANIC; HUMAN; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MEXICO; NUCLEOTIDE SEQUENCE; PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUERTO RICO; STATISTICAL ANALYSIS; ALLELE; CHEMISTRY; COHORT ANALYSIS; COMPARATIVE STUDY; ENVIRONMENTAL EXPOSURE; GENETICS; METABOLISM; OCCUPATIONAL EXPOSURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICS; UNITED STATES;

MAMMALIA; PRIMATES;

ALLELES; COHORT STUDIES; DNA; ENVIRONMENTAL EXPOSURE; GENE FREQUENCY; GENOTYPE; HISPANIC AMERICANS; HUMANS; ISOENZYMES; MEXICAN AMERICANS; OCCUPATIONAL EXPOSURE; OXYGENASES; PHARMACEUTICAL PREPARATIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UNITED STATES;

EID: 9444240466     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001099     Document Type: Article

References (30)

1. Cashman JR (1995) Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem Res Toxicol 8:165-181.
2. Cashman JR (2003) The role of flavin-containing monooxygenase in drug metabolism and development. Curr Opin Drug Discov Dev 6:486-493.
3. Decker CJ and Doerge DR (1991) Rat hepatic microsomal metabolism of ethylenethiourea. Contributions of the flavin-containing monooxygenase and cytochrome P-450 isozymes. Chem Res Toxicol 4:482-489.
4. den Dunnen JT and Antonarakis SE (2001) Nomenclature for the description of human sequence variations. Hum Genet 109:121-124.
5. Dolphin CT, Beckett DJ, Janmohamed A, Cullingford TE, Smith RL, Shephard EA, and Phillips IR (1998) The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein. J Biol Chem 273:30599-30607.
6. Furnes B, Feng J, Sommer SS, and Schlenk D (2003) Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans. Drug Metab Dispos 31:187-193.
7. Henderson MC, Krueger SK, Siddens LK, Stevens JF, and Williams DE (2004a) S-Oxygenation of the thioether organophosphate insecticides phorate and disulfoton by human lung flavin-containing monooxygenase 2. Biochem Pharmacol 68:959-967.
8. Henderson MC, Krueger SK, Stevens JF, and Williams DE (2004b) Human flavin-containing monooxygenase form 2 S-oxygenation: sulfenic acid formation from thioureas and oxidation of glutathione. Chem Res Toxicol 17:633-640.
9. Hernandez D, Janmohamed A, Chandan P, Phillips IR, and Shephard EA (2004) Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 14:117-130.
10. Hines RN, Hopp KA, Franco J, Saeian K, and Begun FP (2002) Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol Pharmacol 62:320-325.
11. Hodgson E, Cherrington N, Coleman SC, Liu S, Falls JG, Cao Y, Goldstein JE, and Rose RL (1998) Flavin-containing monooxygenase and cytochrome P450 mediated metabolism of pesticides: from mouse to human. Rev Toxicol 2:231-243.
12. Karoly ED and Rose RL (2001) Sequencing, expression and characterization of cDNA expressed flavin-containing monooxygenase 2 from mouse. J Biochem Mol Toxicol 15:300-308.
13. Kinsler S, Levi PE, and Hodgson E (1988) Hepatic and extrahepatic microsomal oxidation of phorate by cytochrome P-450 and FAD-containing monooxygenase systems in the mouse. Pest Biochem Physiol 31:54-60.
14. Krieter PA, Ziegler DM, Hill KE, and Burk RF (1984) Increased biliary GSSG efflux from rat livers perfused with thiocarbamide substrates for the flavin-containing monooxygenase. Mol Pharmacol 26:122-127.
15. Krueger SK, Martin SR, Yueh M-F, Pereira CB, and Williams DE (2002a) Identification of active flavin-containing monooxygenase isoform 2 in human lung and characterization of expressed protein. Drug Metab Dispos 30:34-41.
16. Krueger SK, Williams DE, Yueh M-F, Martin SR, Hines RN, Raucy JL, Dolphin CT, Shephard EA, and Phillips IR (2002b) Genetic polymorphisms of flavin-containing monooxygenase (FMO). Drug Metab Rev 34:523-532.
17. Krueger SK, Yueh M-F, Martin SR, Pereira CB, and Williams DE (2001) Characterization of expressed full-length and truncated FMO2 from rhesus monkey. Drug Metab Dispos 29:693-700.
18. Lawton M, Cashman J, Cresteil T, Dolphin C, Elfarra A, Hines RN, Hodgson E, Kimura T, Ozols J, Phillips I, et al. (1994) A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch Biochem Biophys 308:254-257.
19. Levi PE and Hodgson E (1988) Stereospecificity in the oxidation of phorate and phorate sulphoxide by purified FAD-containing monooxygenase and cytochrome P-450 isozymes. Xenobiotica 18:29-39.
20. Raucy JL, Schultz ED, Kearins MC, Arora S, Johnston DE, Omdahl JL, Eckmann L, and Carpenter SP (1999) CYP2E1 expression in human lymphocytes from various ethnic populations. Alcohol Clin Exp Res 23:1868-1874.
21. Raucy JL, Schultz ED, Wester MR, Arora S, Johnston DE, Omdahl JL, and Carpenter SP (1997) Human chlorzoxazone activity. Drug Metab Dispos 25:1429-1435.
22. Scott AM, Powell GM, Upshall DG, and Curtis CG (1990) Pulmonary toxicity of thioureas in the rat. Environ Health Perspect 85:43-50.
23. Shows TB, McAlpine PJ, Boucheix C, Collins FS, Coneally PM, Frezal J, Gershowitz H, Goodfellow PN, Hall IG, Issitt P, et al. (1987) Guidelines for human gene nomenclature. Cytogenet Cell Genet 46:11-28.
24. Smith PB and Crespi C (2002) Thiourea toxicity in mouse C3H/10T1/2 cells expressing human flavin-dependent monooxygenase 3. Biochem Pharmacol 63:1941-1948.
25. Usmani KA, Karoly ED, Hodgson E, and Rose RL (2004) In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily. Drug Metab Dispos 32:333-339.
26. Whetstine JR, Yueh M-F, McCarver DG, Williams DE, Park C-S, Rang JH, Cha Y-N, Dolphin CT, Shephard EA, Phillips IR, and Hines RN (2000) Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans. Toxicol Appl Pharmacol 168:216-224.
27. Williams DE, Hale SE, Muerhoff AS, and Masters BSS (1985) Rabbit lung flavin-containing monooxygenase. Purification, characterization and induction during pregnancy. Mol Pharmacol 28:381-390.
28. Yueh M-F, Krueger SK, and Williams DE (1997) Pulmonary flavin-containing monooxygenase (FMO) in rhesus macaque: expression of FMO2 protein and analysis of the cDNA. Biochim Biophys Acta 1350:267-271.
29. Zheng Y-M, Henne KR, Charmley P, Kim RB, McCarver DG, Cabacungan ET, Hines RN, and Rettie AE (2003) Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. Toxicol Appl Pharmacol 186:119-126.
30. Ziegler DM (2003) An overview of the mechanism, substrate specificities and structure of FMOs. Drug Metab Rev 34:503-511.